Triterpenoids and Chemoprevention: A Dartmouth Collaboration
For 11 years, Dartmouth chemists Gordon Gribble and Tadashi Honda have collaborated with Dr. Michael Sporn, a professor of pharmacology and toxicology at Dartmouth Medical School, to create drugs that prevent and treat cancer. In 1998, Gribble's lab synthesized CDDO, a synthetic triterpenoid. This compound and one of its derivatives are now in Phase I clinical trials for solid tumors and leukemia. To learn more about the Dartmouth triterpenoid project and chemoprevention, read "Compound Interest".
A Q&A with Gordon Gribble
- What are triterpenoids?
- How did you create the synthetic triterpenoids?
- How did you begin working with Dr. Sporn?
- Why has your collaboration with Dr. Sporn been so successful?
- How do triterpenoids relate to cancer prevention?
- Do academic chemists often see their compounds go into trials?
If you'd like to offer feedback about this article, we'd welcome getting your comments at DartMed@Dartmouth.edu.
This article may not be reproduced or reposted without permission. To inquire about permission, contact DartMed@Dartmouth.edu.